Investors

Presentations & Reports

Presentations & Reports

2020

For investor-related information please contact Ronn Bechler at Automic Group
Ph: +61 (0) 400 009 774 E: ronn.bechler@automicgroup.com.au

2023 AGM Webinar Presentation
2023 AGM Webinar Presentation

Chairman Osagie Imasogie and CEO Dr Oludare Odumosu deliver the AGM presentation

Investor Webinar: Top line trial results of Zelira’s diabetic nerve pain drug vs Lyrica®

Osagie Imasogie (Chairman) and Oludare Odumosu (Global CEO) take investors and analysts through the top line comparative trial results of Zelira’s diabetic nerve pain drug vs Lyrica® including efficacy, safety and next steps for the organisation.

Zelira Half Yearly Report FY22/23
Hannam and Partners Investor Report – Zelira completes enrolment in Diabetic Nerve Pain trial

H&P’s updated report on Zelira highlighted by the completed enrolment of participants in the diabetic nerve pain trial

Zelira AGM Presentation 2022

Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Oludare Odumosu present a company update at the 2022 Annual General Meeting.

Zelira CEO Oludare Odumosu speaks with Proactive

Zelira Global CEO Oludare Odumosu provides Proactive with an update on the company’s progress with its proprietary revenue-generating products, global expansion and its pipeline of candidates undergoing clinical development.

Zelira Therapeutics’ commercialisation program

Zelira to launch a suite of new cannabinoid-based products in FY22 – Proactive

Channel 9 News Perth

Zelira Therapeutics and Curtin University partner on research of proprietary technology that demonstrates significant uptake of CBD into the brain

Presentation at Cantor Fitzgerald International Cannabis Forum

Zelira Therapeutics Investor Slide Deck

Proactive – Zelira Therapeutics forms exclusive licensing deal to distribute its HOPE products in Washington DC

Zelira Therapeutics forms exclusive licensing deal to distribute its HOPE products in Washington DC

Proactive – Zelira Therapeutics and Emyria team up for ‘disruptive’ autism spectrum disorder trial

Some excerpt

Investor Presentation – Non-Deal Roadshow
Proactive Interview – Zelira Therapeutics on its acquisition with Ilera
CFN Media Interviews Zelda Therapeutics at New West Summit
Zelda Therapeutics – Investor Teleconference, 16 October 2019
Zelda Therapeutics poised to ‘value add al the way from clinical trails to the market’.
Zelda Therapeutics poised to ‘value add all the way from clinical trails to the market’
AGM Presentation – Non-deal Roadshow
AGM Presentation
Investor Presentation
Investor Presentation
Investor Presentation

Start typing and press Enter to search

Shopping Cart